Dan Nomura is a Professor of Chemical Biology and Molecular Therapeutics in the Department of Chemistry and the Department of Molecular and Cell Biology in the Division of Molecular Therapeutics at the University of California, Berkeley. He is the Co-Director of the Molecular Therapeutics Initiative and an Investigator at the Innovative Genomics Institute at UC Berkeley. Since 2017, he has been the Director of the Novartis-Berkeley Translational Chemical Biology Institute focused on using chemoproteomic platforms to tackle the undruggable proteome. He is Co-Founder of Frontier Medicines and Zenith Therapeutics. He is on the Scientific Advisory Boards for Frontier Medicines, Zenith, Photys Therapeutics, Apertor Pharma, Oerth Bio, Axiom Therapeutics, Deciphera, and Ten30 Biosciences. Nomura has also been on the scientific advisory committees of The Mark Foundation for Cancer Research since 2020 and American Association for Cancer Research (AACR) since 2025. He is also an Investment Advisory Partner at a16z Bio+Health, an Investment Advisory Board member at Droia Ventures, and an iPartner with The Column Group. In 2025, Nomura also became the Editor-in-Chief for Molecular Cancer Therapeutics. He earned his B.A. in Molecular and Cell Biology in 2003 and Ph.D. in Molecular Toxicology in 2008 at UC Berkeley with Professor John Casida and was a postdoctoral fellow at Scripps Research with Professor Benjamin F. Cravatt before returning to Berkeley as a faculty member in 2011. Among his honors are the National Cancer Institute Outstanding Investigator Award, Searle Scholar, and the Mark Foundation for Cancer Research ASPIRE award.
